Based on the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, the new consensus-based recommendations from EAS and EFLM are now available.
The 2019 ESC/EAS Guidelines recommend the Lp(a) analysis for the population over 40-years-old, in order to identify individuals with a high risk to develop atherosclerotic cardiovascular disease. Clinicians claim that a one-off measurement of Lp(a) may help to identify people with very high inherited Lp(a) levels, who may have a substantial lifetime risk of atherosclerotic cardiovascular disease. A high Lp(a) plasma level may also be helpful in further risk stratification of patients at high risk of this disease, in patients with a family history of premature cardiovascular disease and in order to determine treatment strategies in people, whose estimated risk is on the border of risk categories.
On the light of this, the EAS and EFLM have recently published the new consensus-based recommendations for quantifying atherogenic lipoproteins (full text available here).
This document summarizes the consensus-based recommendations of this expert panel and aims to provide appropriate guidance on the pre-analytical, analytical and post-analytical phases of laboratory testing of atherogenic lipoproteins measured and reported by the clinical laboratories worldwide.
Sentinel’s Lp(a) Ultra (Ref. 11504D) is an Immunoturbidimetric quantitative test for the determination of Lp(a) in serum or plasma. It is available on most of the Clinical Chemistry platforms and has many benefits:
- Determination via latex-enhanced technology → for an optimal sensitivity
- Fully automated testing → to minimize Laboratory workload
- Liquid and ready-to-use reagents → which constitute an easy and convenient formulation
- Measuring range: 3 – 130 mg/dL → for an accurate measurement of all samples
- Determination in serum and plasma → to allow versatile choice of samples
- No prozone effect at least up to 660 mg/dL → to minimize the risk of incorrect results
Sentinel Lp(a) Ultra assay (Ref. 11504D) is standardized to the WHO-IFCC Reference Material SRM2B, reagent/calibrator lot and instrument dependent, that allows to express the results in nmol/L, measuring units are available in nmol/L upon request. Results expressed in nmol/L are not affected by any possible Apo(a) size-related bias, as recommended by the International Federation of Clinical Chemistry (IFCC) Working Group on Lp(a).